ArticleIndian pediatrics2025
Diagnostic and Prognostic Performance of Proadrenomedullin Versus Procalcitonin in Children with Cancer and Febrile Neutropenia.
Article in Indian pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPrimary objective was to compare the performance of proadrenomedullin (ProADM) and procalcitonin (PCT) for diagnosing clinically documented infections (CDI)/microbiologically documented infections (MDI)/fever without focus (NF) in children with cancer having febrile neutropenia (FN). The secondary objective was to compare the prognostic utility of PCT and ProADM for identifying adverse clinical outcome.
methodsCancer patients (aged ≤ 18 years) presenting with FN were included; those who had received antibiotics within the last 14 days were excluded. Serum PCT and ProADM were estimated on days 1, 3 and 7 of enrolment. Adverse outcome was defined in terms of clinical non-response and day 30 mortality.
resultsWe recruited 345 children. PCT in children with MDI were significantly higher than those with CDI on day 1 (P = 0.031) and day 7 (P < 0.001); PCT ≥ 0.21 ng/mL on day 1 had a 77% sensitivity and 44% specificity for diagnosis of MDI; the area under receiver operating characteristic curve (95 CI%) 0.601 (0.49, 0.71). ProADM did not differentiate between MDI and CDI. PCT and ProADM on day 1 did not predict the need for second line antibiotics. PCT ≥ 0.21 ng/mL on day 1 was predictive of MDI (P = 0.041) and PCT ≥ 1.77 ng/mL on day 7 was an independent predictor of day-30 mortality.
conclusionsPCT is effective in differentiating between MDI, CDI, and NF in children with FN, and also predicts the day 30 mortality.
Indexed as
Identifiers
40126848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.